Eikon Therapeutics, Inc. Common Stock
EIKN
NASDAQ·Healthcare·Biotechnology·Mkt cap $587.9M
$10.86
▼ -0.91%
P/E
-3.44
Mkt Cap
$587.9M
52-Wk Range
$7.90–$17.40
52-Week Range
$7.90 - $17.40
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 27.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary platform for precise protein interaction characterization in living cells
- Brain-penetrant PARP1 inhibitor addressing underserved brain metastases market
- Multi-targeted pipeline addressing multiple high-incidence cancer types
- First-mover advantage in selective PARP1 and WRN helicase inhibitor space
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Clinical trial progression and regulatory approvals for lead candidates
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+20.9% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying EIKN right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Sep 2, 2026
AUG 13, 2026
Reported EPS of -$1.63 vs -$1.58 consensus (-3.2% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-3.2%
Revenue trend · last 2Q
—
—
Q1 26
Q2 26
$0
$0
Margins · last 2Q
No margin history available.
Wall Street consensus
2 analysts · 50% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
50%
Hold
0%
Sell
50%
Median Price Target
—
Latest: Cantor Fitzgerald · Aug 21, 2026
vs Industry
How EIKN stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related